Symbols / DMAC Stock $6.26 -0.95% DiaMedica Therapeutics Inc.

Healthcare • Biotechnology • United States • NCM
DMAC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Dietrich John Pauls MBA
Exch · Country NCM · United States
Market Cap 337.31M
Enterprise Value 289.42M
Income -35.10M
Sales —
FCF (ttm) -18.01M
Book/sh 1.04
Cash/sh 0.95
Employees 35
Insider 10d —
IPO Aug 03, 2012
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.11
PEG —
P/S —
P/B 6.00
P/C —
EV/EBITDA -7.89
EV/Sales —
Quick Ratio 8.98
Current Ratio 9.11
Debt/Eq 0.45
LT Debt/Eq —
EPS (ttm) -0.71
EPS next Y -0.88
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-05-06
ROA -49.96%
ROE -86.47%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 53.88M
Shs Float 28.43M
Insider Own 27.74%
Instit Own 38.42%
Short Float 13.55%
Short Ratio 26.32
Short Interest 4.90M
52W High 10.42
vs 52W High -39.92%
52W Low 3.48
vs 52W Low 80.14%
Beta 0.99
Impl. Vol. 1.71%
Rel Volume 0.73
Avg Volume 198.32K
Volume 145.20K
Target (mean) $15.50
Tgt Median $13.00
Tgt Low $11.00
Tgt High $25.00
# Analysts 4
Recom Strong_buy
Prev Close $6.32
Price $6.26
Change -0.95%
About

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$15.50
Mean price target
2. Current target
$6.26
Latest analyst target
3. DCF / Fair value
$-6.02
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.26
Low
$11.00
High
$25.00
Mean
$15.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-11-14 init Cantor Fitzgerald — → Overweight $25
2025-08-15 reit HC Wainwright & Co. Buy → Buy $12
2025-07-18 main Craig-Hallum Buy → Buy $11
2025-07-18 main Lake Street Buy → Buy $14
2025-07-18 main HC Wainwright & Co. Buy → Buy $12
2025-05-29 reit HC Wainwright & Co. Buy → Buy $10
2025-03-19 main HC Wainwright & Co. Buy → Buy $10
2024-11-15 reit HC Wainwright & Co. Buy → Buy $7
2024-10-10 reit HC Wainwright & Co. Buy → Buy $7
2024-10-07 init HC Wainwright & Co. — → Buy $7
2024-08-16 reit Oppenheimer Outperform → Outperform $6
2024-03-21 main Craig-Hallum Buy → Buy $8
2024-03-21 reit Oppenheimer Outperform → Outperform $6
2023-06-22 up Oppenheimer Perform → Outperform $7
2022-07-07 main Lake Street — → Buy $8
2022-07-07 main Craig-Hallum — → Buy $12
2022-07-07 down Oppenheimer Outperform → Perform —
2021-06-30 main Roth Capital — → Buy $32
2021-04-08 init Oppenheimer — → Outperform $27
2021-02-17 init Roth Capital — → Buy $38
News
RSS: Latest DMAC news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-02 PARSONS JAMES T CPA Director — 10,095 $8.42 $85,000
2026-01-02 GIUFFRE RANDALL MICHAEL M.D. Director — 6,175 $8.42 $51,994
2026-01-02 SEMBA CHARLES PAULING Director — 3,355 $8.42 $28,249
2025-11-25 STAHLBERG JAN Beneficial Owner of more than 10% of a Class of Security — 1,061,277 $6.52 $7,631,469
2025-11-21 PARSONS JAMES T CPA Director — 12,000 $2.20 $26,400
2025-08-27 STAHLBERG JAN Beneficial Owner of more than 10% of a Class of Security — 1,000,000 $5.86 $5,958,107
2025-07-23 JACINTO RICHARD II Beneficial Owner of more than 10% of a Class of Security — 400,000 $5.15 $2,060,000
2025-07-23 VON KOCH NILS THOMAS Beneficial Owner of more than 10% of a Class of Security — 2,857,142 $5.15 $14,714,281
2025-07-23 STAHLBERG JAN Beneficial Owner of more than 10% of a Class of Security — 1,542,857 $5.15 $7,945,714
2025-04-07 PILNIK RICHARD D Director — 24,000 $2.11 $50,640
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
34.40
+28.92%
26.68
+25.46%
21.27
+51.90%
14.00
Research And Development
24.61
+29.16%
19.06
+45.36%
13.11
+67.24%
7.84
Selling General And Administration
9.78
+28.32%
7.62
-6.53%
8.16
+32.38%
6.16
General And Administrative Expense
9.78
+28.32%
7.62
-6.53%
8.16
+32.38%
6.16
Other Gand A
9.78
+28.32%
7.62
-6.53%
8.16
+32.38%
6.16
Total Expenses
34.40
+28.92%
26.68
+25.46%
21.27
+51.90%
14.00
Operating Income
-34.40
-28.92%
-26.68
-25.46%
-21.27
-51.90%
-14.00
Total Operating Income As Reported
-34.40
-28.92%
-26.68
-25.46%
-21.27
-51.90%
-14.00
EBITDA
-34.35
-28.95%
-26.64
-25.45%
-21.24
-51.95%
-13.98
Normalized EBITDA
-34.35
-28.95%
-26.64
-25.45%
-21.24
-51.95%
-13.98
Reconciled Depreciation
0.04
+10.26%
0.04
+30.00%
0.03
+20.00%
0.03
EBIT
-34.40
-28.92%
-26.68
-25.46%
-21.27
-51.90%
-14.00
Net Income
-32.77
-34.05%
-24.44
-26.12%
-19.38
-41.72%
-13.68
Pretax Income
-32.74
-34.10%
-24.41
-26.25%
-19.34
-41.69%
-13.65
Other Income Expense
1.66
-26.82%
2.27
+17.52%
1.93
+446.46%
0.35
Other Non Operating Income Expenses
1.66
-26.82%
2.27
+17.52%
1.93
+446.46%
0.35
Tax Provision
0.03
-6.67%
0.03
-30.23%
0.04
+53.57%
0.03
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-32.77
-34.05%
-24.44
-26.12%
-19.38
-41.72%
-13.68
Net Income From Continuing Operation Net Minority Interest
-32.77
-34.05%
-24.44
-26.12%
-19.38
-41.72%
-13.68
Net Income From Continuing And Discontinued Operation
-32.77
-34.05%
-24.44
-26.12%
-19.38
-41.72%
-13.68
Net Income Continuous Operations
-32.77
-34.05%
-24.44
-26.12%
-19.38
-41.72%
-13.68
Normalized Income
-32.77
-34.05%
-24.44
-26.12%
-19.38
-41.72%
-13.68
Net Income Common Stockholders
-32.77
-34.05%
-24.44
-26.12%
-19.38
-41.72%
-13.68
Diluted EPS
-0.70
-16.67%
-0.60
+0.00%
-0.60
-15.38%
-0.52
Basic EPS
-0.70
-16.67%
-0.60
+0.00%
-0.60
-15.38%
-0.52
Basic Average Shares
46.98
+16.28%
40.40
+24.07%
32.57
+23.16%
26.44
Diluted Average Shares
46.98
+16.28%
40.40
+24.07%
32.57
+23.16%
26.44
Diluted NI Availto Com Stockholders
-32.77
-34.05%
-24.44
-26.12%
-19.38
-41.72%
-13.68
Line Item Trend 2023-12-31
Total Assets
54.16
Current Assets
53.67
Cash Cash Equivalents And Short Term Investments
52.90
Cash And Cash Equivalents
4.54
Other Short Term Investments
48.35
Receivables
0.37
Accounts Receivable
0.07
Other Receivables
—
Accrued Interest Receivable
0.30
Prepaid Assets
0.41
Other Current Assets
0.41
Total Non Current Assets
0.48
Net PPE
0.48
Gross PPE
0.58
Accumulated Depreciation
-0.10
Properties
0.00
Buildings And Improvements
0.35
Machinery Furniture Equipment
0.21
Other Properties
—
Leases
0.02
Non Current Deferred Assets
—
Non Current Prepaid Assets
0.00
Total Liabilities Net Minority Interest
3.10
Current Liabilities
2.79
Payables And Accrued Expenses
1.94
Payables
0.93
Accounts Payable
0.93
Current Accrued Expenses
1.01
Pensionand Other Post Retirement Benefit Plans Current
0.77
Current Debt And Capital Lease Obligation
0.08
Current Capital Lease Obligation
0.08
Total Non Current Liabilities Net Minority Interest
0.32
Long Term Debt And Capital Lease Obligation
0.32
Long Term Capital Lease Obligation
0.32
Stockholders Equity
51.06
Common Stock Equity
51.06
Capital Stock
0.00
Common Stock
0.00
Share Issued
37.96
Ordinary Shares Number
37.96
Treasury Shares Number
0.00
Additional Paid In Capital
166.61
Retained Earnings
-115.56
Gains Losses Not Affecting Retained Earnings
0.01
Other Equity Adjustments
0.01
Total Equity Gross Minority Interest
51.06
Total Capitalization
51.06
Working Capital
50.89
Invested Capital
51.06
Total Debt
0.40
Capital Lease Obligations
0.40
Net Tangible Assets
51.06
Tangible Book Value
51.06
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-29.06
-31.65%
-22.08
-17.88%
-18.73
-62.70%
-11.51
Cash Flow From Continuing Operating Activities
-29.06
-31.65%
-22.08
-17.88%
-18.73
-62.70%
-11.51
Net Income From Continuing Operations
-32.77
-34.05%
-24.44
-26.12%
-19.38
-41.72%
-13.68
Depreciation Amortization Depletion
0.04
+10.26%
0.04
+30.00%
0.03
+20.00%
0.03
Depreciation
0.04
+10.26%
0.04
+30.00%
0.03
+20.00%
0.03
Depreciation And Amortization
0.04
+10.26%
0.04
+30.00%
0.03
+20.00%
0.03
Other Non Cash Items
0.08
+9.33%
0.07
+7.14%
0.07
+9.38%
0.06
Stock Based Compensation
3.85
+84.46%
2.08
+23.89%
1.68
+12.05%
1.50
Change In Working Capital
0.68
-55.36%
1.51
+1525.81%
0.09
-84.10%
0.58
Change In Receivables
-0.02
-116.54%
0.13
+146.34%
-0.29
-697.92%
0.05
Change In Prepaid Assets
1.05
+193.77%
-1.12
-602.50%
-0.16
-196.30%
-0.05
Change In Payables And Accrued Expense
-0.36
-114.26%
2.50
+363.52%
0.54
-8.63%
0.59
Change In Accrued Expense
-0.89
-135.84%
2.49
+615.23%
0.35
-4.92%
0.37
Change In Payable
0.54
+3721.43%
0.01
-92.71%
0.19
-14.67%
0.23
Change In Account Payable
0.54
+3721.43%
0.01
-92.71%
0.19
-14.67%
0.23
Investing Cash Flow
-2.19
-125.60%
8.56
+146.80%
-18.30
-258.60%
11.54
Cash Flow From Continuing Investing Activities
-2.19
-125.60%
8.56
+146.80%
-18.30
-258.60%
11.54
Net PPE Purchase And Sale
-0.04
-60.00%
-0.03
-4.17%
-0.02
+70.37%
-0.08
Purchase Of PPE
-0.04
-60.00%
-0.03
-4.17%
-0.02
+70.37%
-0.08
Sale Of PPE
—
—
—
0.00
Capital Expenditure
-0.04
-60.00%
-0.03
-4.17%
-0.02
+70.37%
-0.08
Net Investment Purchase And Sale
-2.15
-125.06%
8.59
+147.00%
-18.27
-257.29%
11.62
Purchase Of Investment
-59.28
-17.59%
-50.41
+27.37%
-69.41
-51.94%
-45.68
Sale Of Investment
57.13
-3.18%
59.00
+15.38%
51.13
-10.76%
57.30
Financing Cash Flow
43.88
+265.82%
11.99
-67.44%
36.84
+614133.33%
-0.01
Cash Flow From Continuing Financing Activities
43.88
+265.82%
11.99
-67.44%
36.84
+614133.33%
-0.01
Net Issuance Payments Of Debt
-0.01
-11.11%
-0.01
-50.00%
-0.01
+0.00%
-0.01
Repayment Of Debt
-0.01
-11.11%
-0.01
-50.00%
-0.01
+0.00%
-0.01
Long Term Debt Payments
-0.01
-11.11%
-0.01
-50.00%
-0.01
+0.00%
-0.01
Net Long Term Debt Issuance
-0.01
-11.11%
-0.01
-50.00%
-0.01
+0.00%
-0.01
Net Common Stock Issuance
43.28
+268.45%
11.75
-68.12%
36.85
0.00
Proceeds From Stock Option Exercised
1.00
+292.19%
0.26
0.00
0.00
Net Other Financing Charges
-0.40
—
—
—
Changes In Cash
12.62
+931.49%
-1.52
-720.54%
-0.18
-980.95%
0.02
Beginning Cash Position
3.02
-33.41%
4.54
-3.91%
4.73
+0.45%
4.71
End Cash Position
15.65
+417.26%
3.02
-33.41%
4.54
-3.91%
4.73
Free Cash Flow
-29.10
-31.68%
-22.10
-17.86%
-18.75
-61.77%
-11.59
Income Tax Paid Supplemental Data
0.03
+7.69%
0.03
-21.21%
0.03
+22.22%
0.03
Amortization Of Securities
-0.94
+29.86%
-1.34
-9.81%
-1.22
-11018.18%
-0.01
Common Stock Issuance
43.28
+268.45%
11.75
-68.12%
36.85
0.00
Issuance Of Capital Stock
43.28
+268.45%
11.75
-68.12%
36.85
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category